Introduction: the overlooked incretin

When the incretin concept emerged in the 1960s, two hormones shared the stage: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). While GLP-1 receptor agonists dominated the first generation of metabolic peptide pharmacology, GIP was largely side-lined — partly because circulating GIP levels are paradoxically elevated in type 2 diabetes, which was (incorrectly) interpreted as receptor-level resistance arguing against therapeutic relevance. The arrival of tirzepatide overturned that view emphatically. Understanding GIP receptor (GIPR) biology is now essential for any researcher working with next-generation metabolic agents.

K-cell secretion and endogenous GIP physiology

GIP is a 42-amino-acid peptide synthesised and secreted by K-cells — specialised enteroendocrine cells concentrated in the duodenum and proximal jejunum. Nutrient ingestion, particularly dietary fat and rapidly absorbed carbohydrates, is the primary secretagogue; GIP release occurs within minutes of luminal exposure. In healthy adults, GIP is the quantitatively dominant incretin, typically accounting for more than half of the total incretin effect on insulin secretion in the postprandial state.

Native GIP has a plasma half-life of approximately 5–7 minutes, again curtailed by DPP-4 cleavage at the N-terminal position. Engineered GIPR agonists (such as the GIP moiety within tirzepatide) incorporate fatty-acid conjugation for albumin binding, extending the effective half-life to several days to support once-weekly dosing.

Receptor pharmacology: GIPR as a Class B GPCR

The GIP receptor belongs to the Class B (secretin family) of G-protein-coupled receptors, sharing structural homology with GLP-1R, glucagon receptor (GcgR), and the GHRH receptor. Class B GPCRs are characterised by a large extracellular N-terminal domain that contributes substantially to ligand binding. GIPR couples primarily to the Gαs subunit, elevating intracellular cyclic AMP (cAMP). Downstream, cAMP activates both protein kinase A (PKA) and the exchange protein directly activated by cAMP (EPAC), each mediating distinct cellular responses depending on cell type.

GIPR expression is notably broad: pancreatic β-cells and α-cells, adipocytes (both subcutaneous and visceral), osteoblasts, gastric mucosal cells, cortical neurons, hypothalamic appetite nuclei, and — importantly — resident macrophages and dendritic cells within the adipose stromal-vascular fraction. This multi-tissue distribution means GIPR agonism produces a more diffuse metabolic effect than GLP-1R agonism alone.

Pancreatic effects: beyond glucose-stimulated insulin release

On pancreatic β-cells, GIPR agonism potentiates glucose-stimulated insulin secretion through cAMP/PKA-mediated closure of ATP-sensitive potassium channels and facilitation of calcium influx — mechanisms broadly shared with GLP-1R. However, GIP also has direct effects on α-cells, modulating glucagon secretion in a context-dependent manner: raising glucagon under hypoglycaemic conditions (contributing to glucose counter-regulation) and suppressing it post-prandially alongside GLP-1. This dual regulation may explain part of the superior glycaemic control observed with dual agonists.

Adipose-tissue GIP receptor expression: the key differentiator

GIPR expression on mature adipocytes is arguably the most therapeutically consequential aspect of GIP biology in the context of weight-loss pharmacology. Adipocyte GIPR activation promotes:

Lipolysis regulation: Under fasting conditions, GIPR-mediated cAMP signalling enhances hormone-sensitive lipase (HSL) activity, increasing fatty-acid release. Post-prandially, co-stimulation with insulin shifts adipocyte GIPR signalling towards lipid uptake and re-esterification — a mechanism that fine-tunes fat storage and mobilisation in concert with the fed/fasted cycle.
Adiponectin secretion: GIPR agonism upregulates adiponectin expression in cultured adipocytes, with potential downstream benefits on insulin sensitivity in muscle and liver.
Adipocyte differentiation: Pre-adipocyte differentiation is modulated by GIPR signalling, with evidence that chronic GIPR agonism may influence adipocyte size distribution — shifting the adipose depot towards smaller, more metabolically active cells.

Insulin sensitisation and hepatic lipid clearance

In skeletal muscle and liver, GIPR expression supports insulin-sensitising effects independent of weight loss. Hepatic GIPR activation is associated with reduced intrahepatic triglyceride accumulation, with mechanistic evidence pointing to cAMP-dependent suppression of lipogenic gene expression and enhanced fatty-acid β-oxidation. This provides a plausible biological explanation for the preferential visceral fat loss and hepatic steatosis improvement observed in SURMOUNT programme participants on tirzepatide.

GIP modulation of macrophage activity

Adipose tissue inflammation — driven by pro-inflammatory M1-type macrophage infiltration — is a central pathophysiological feature of obesity-related metabolic dysfunction. GIPR is expressed on both circulating monocytes and tissue-resident macrophages. GIPR agonism promotes a shift towards anti-inflammatory M2 macrophage polarisation through cAMP-mediated suppression of NF-κB signalling and reduced pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β). This immune-modulatory dimension of GIP receptor biology extends the metabolic benefit of GIPR agonism beyond direct lipid and glucose effects.

GIP vs GLP-1: complementary, not redundant

Early concerns that GIP and GLP-1 were simply redundant incretins have given way to a nuanced picture of complementary receptor distribution and signalling. GLP-1R dominates in brainstem appetite circuits and gastric smooth muscle; GIPR is predominant in adipose tissue and has a more substantial bone-anabolic effect (GIPR agonism is associated with reduced bone resorption markers). In the context of a dual agonist, the two receptor systems work additively — GLP-1R driving central appetite suppression and gastric emptying delay, GIPR driving peripheral lipid partitioning and insulin sensitisation.

A relevant observation from tirzepatide clinical pharmacology: at equivalent degrees of weight loss versus semaglutide, tirzepatide-treated participants show proportionally greater fat mass reduction and lean mass preservation — consistent with GIPR-mediated adipose-tissue effects contributing to body composition over and above caloric restriction.

How tirzepatide and retatrutide exploit GIPR

Tirzepatide is a single peptide molecule engineered to act as a balanced dual agonist at both GIPR and GLP-1R. Its GIPR potency approximates that of native GIP; its GLP-1R potency is slightly lower than semaglutide on a molar basis, yet clinical weight-loss outcomes substantially exceed semaglutide — underlining that GIPR co-agonism provides additive rather than redundant metabolic benefit.

Retatrutide extends this strategy further by adding glucagon receptor (GcgR) agonism to create a triple incretin. The glucagon component raises hepatic energy expenditure and resting metabolic rate (see the glucagon receptor pharmacology guide). In Phase 2 data, retatrutide achieved mean body weight reductions exceeding 17% at 24 weeks — substantially beyond dual GIP/GLP-1 agonism — with the GIPR-mediated adipose effects remaining central to its mechanism.

Trial data: SURMOUNT-1 and adipose partitioning

The SURMOUNT-1 trial (tirzepatide 5, 10, and 15 mg vs placebo in adults with obesity, without diabetes) demonstrated mean weight reductions of 15–20.9% at 72 weeks on the highest dose. Crucially, body composition sub-studies demonstrated preferential visceral adipose tissue (VAT) reduction — disproportionate relative to total weight loss — consistent with GIPR expression being enriched in visceral adipocytes. VAT reduction is mechanistically important because visceral fat drives hepatic insulin resistance, systemic inflammation, and cardiovascular risk more powerfully than subcutaneous fat.

Complementary data from SURMOUNT-3 (tirzepatide following intensive lifestyle intervention) and the cardiometabolic sub-analysis of SURPASS-CVOT reinforce the adipose-targeted biology: improvements in triglycerides, HDL, and hepatic fat fraction exceeded what could be predicted from weight loss alone, pointing to direct GIPR-driven lipid effects.

Why this matters for next-generation compounds

The validation of GIPR as a druggable obesity target has catalysed a second wave of compound development. Researchers are now exploring GIPR antagonism as an adjunct to GLP-1R agonism (the counterintuitive "GIPR antagonist + GLP-1R agonist" approach explored by Amgen with AMG-133 also shows efficacy, suggesting receptor biology remains complex and context-dependent). Multi-receptor peptides engaging GIPR, GLP-1R, GcgR, and potentially FGF21 receptor are in early clinical programmes. Understanding the tissue-specific and signalling-cascade differences between GIPR and GLP-1R is fundamental to evaluating any next-generation dual or triple agonist.